z-logo
open-access-imgOpen Access
Identification and Evaluation of Apoptosis-Inducing Activity of Ipomone from Ipomoea nil: A Novel, Unusual Bicyclo-[3.2.1] Octanone Containing Gibberic Acid Diterpenoid
Author(s) -
Bharat Goel,
Essha Chatterjee,
Biswajit Dey,
Nancy Tripathi,
Nidhi Bhardwaj,
Arun Khattri,
Santosh Kumar Guru,
Shreyans K. Jain
Publication year - 2021
Publication title -
acs omega
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.779
H-Index - 40
ISSN - 2470-1343
DOI - 10.1021/acsomega.0c06304
Subject(s) - stereochemistry , apoptosis , terpenoid , chemistry , two dimensional nuclear magnetic resonance spectroscopy , poly adp ribose polymerase , cytotoxicity , downregulation and upregulation , biochemistry , in vitro , enzyme , polymerase , gene
Ipomone ( 1 ), a novel diterpenoid along with seven known compounds ( 2 - 8 ), was isolated for the first time from the acidified hydroalcoholic extract of Ipomoea nil seeds. The structures of the isolated compounds were elucidated via comprehensive NMR spectroscopic data. The absolute configuration of 1 was ascertained through NOESY, NMR, and ECD analyses. Compound 1 was found to contain an unusual bicyclo-[3.2.1] octanone, which appeared first time in any natural product that might be an artifact resulting from the acid-catalyzed 1,2 alkyl shift/rearrangement. The novel compound was screened for cytotoxic activity against a panel of 12 human cancer cell lines and exhibited weak cytotoxicity with IC 50 values in the range of 34-86 μM (except for HEK-293 cells). Microscopic studies revealed that compound 1 induced apoptosis and autophagy in A549 cells. To further explore the signaling pathway involved, immunoblot analysis was performed that confirmed inhibition of apoptotic proteins PARP-1 and caspase-3 expression and upregulation of LC3B expression by compound 1 . The compound was further subjected to molecular docking studies to evaluate its binding affinity with p110α, PARP-1, and caspase-3 proteins.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here